Latest news with #StanDruckenmiller
Yahoo
8 hours ago
- Business
- Yahoo
Goldman Sachs Starts Teva Pharma (TEVA) at Buy on Branded Drug Growth
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of billionaire Stan Druckenmiller's top stock picks with huge upside potential. Goldman Sachs analysts began coverage of Teva Pharmaceutical Industries Limited (NYSE:TEVA) with a Buy rating and a price target of $24, on June 6. The analysts' optimistic view was driven in part by a strengthening core business and growth possibilities in the branded segment. According to the analysts, Teva's branded segment, which includes medications like Austedo, Uzedy, Ajovy, and LAI olanzapine, has significant growth potential. They estimate that these assets will generate substantial growth in fiscal year 2027, around 10% higher than the mainstream projections. This optimism stems from recent script data and commercial investments, including direct-to-consumer marketing. On the other hand, Goldman Sachs analysts see modest growth in the generics sector over the upcoming years. Although Teva's growing portfolio of biosimilars—five more are anticipated to be introduced in the United States between fiscal years 2025 and 2027—offers potential, the gRevlimid settlement's expiration in 2026 may offset this growth. Teva Pharmaceutical Industries Limited (NYSE:TEVA) is a multinational pharmaceutical company based in Israel. Although generic medications are Teva's primary area of expertise, the company also has branded drug assets. While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.
Yahoo
11 hours ago
- Business
- Yahoo
JPMorgan Raises Coherent (COHR) Price Target on Strong Growth Outlook
Coherent Corp. (NYSE:COHR) is one of billionaire Stan Druckenmiller's top stock picks with huge upside potential. On June 12, JPMorgan maintained its Overweight rating on Coherent Corp. (NYSE:COHR) but increased its price target from $86 to $100. The upsurge is a result of JPMorgan's growing confidence in the company's ability to meet its investor day goals. The firm modified its projections to take into consideration Coherent's anticipated trajectory of growth and profitability. In fiscal 2026 and 2027, JPMorgan now projects a 10% increase in revenue, with gross margins of roughly 39% in fiscal year 2026 and 40% in fiscal year 2027. The projected results translate into earnings per share forecasts of $4.50 in FY26 and $5.70 in FY27, which puts JPMorgan's FY27 estimates 4% higher than the consensus. Despite finding 'multiple levers of upside' to these assumptions, the firm stated that it is making the cautious assumption that Coherent Corp. (NYSE:COHR) would meet its three to four-year targets in four years as opposed to three. Coherent Corp. (NYSE:COHR) designs and manufactures optoelectronic components, networking solutions, engineered materials, and laser systems for the industrial, communications, electronics, and instrumentation markets. While we acknowledge the potential of COHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Se produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información
Yahoo
11 hours ago
- Business
- Yahoo
Piper Sandler Reaffirms Overweight Rating on BridgeBio Ahead of Phase 3 CALIBRATE Results
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of billionaire Stan Druckenmiller's top stock picks with huge upside potential. With a price target of $63, Piper Sandler analysts reaffirmed their Overweight rating for BridgeBio Pharma, Inc. (NASDAQ:BBIO) on June 6. The analysts drew attention to the upcoming Phase 3 topline readout of the CALIBRATE study for BridgeBio Pharma's calcilytic medication encaleret. The study's findings are expected to be made public in the second half of 2025. According to the analysts, the CALIBRATE study, which includes 67 individuals with autosomal dominant hypocalcemia type 1 (ADH1), is expected to have a favorable outcome given the positive efficacy findings from the Phase 2b study of encaleret in patients with ADH1. With a 40% discount, they calculated that risk-adjusted peak sales for ADH1 in the American and EU markets would amount to $389 million. This figure is equivalent to about 9% of BridgeBio Pharma's overall product revenue. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a biopharmaceutical company that was founded to discover, develop, evaluate, and market cutting-edge medication to cure genetic illnesses. While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.
Yahoo
11 hours ago
- Business
- Yahoo
DocuSign Misses Billings Targets, RBC Maintains Price Target Despite Weak Outlook
DocuSign Inc. (NASDAQ:DOCU) is one of billionaire Stan Druckenmiller's top stock picks with huge upside potential. RBC Capital analysts maintained their price target at $90 for DocuSign Inc. (NASDAQ:DOCU) alongside a Sector Perform rating on June 6. The update followed the company's recent quarterly report, which revealed mixed results. Stocks DocuSign Inc. (NASDAQ:DOCU)reported weaker-than-expected billings growth, which contributed to the company's price falling by 17% during after-hours trading. The company reported that despite its net revenue retention (NRR) staying steady at 101%, its billings growth was just 4% greater year-over-year, falling short of both guidance and the consensus. The company also updated its fiscal year 2026 billings projection, reducing it by $15 million below the midpoint consensus. In addition, the second quarter billings guidance fell short of expectations. That said, improved gross retention along with increased IAM upsells might lead to increases in dollar net retention over the year, according to management. DocuSign Inc. (NASDAQ:DOCU) is a global provider of electronic signature solutions. It delivers document generation, contract lifecycle management (CLM), and an AI-powered Intelligent Agreement Management (IAM) platform. While we acknowledge the potential of DOCU as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
11 hours ago
- Business
- Yahoo
Eli Lilly (LLY) Retains $1,100 Price Target at Bernstein Ahead of Diabetes Conference
Eli Lilly & Company (NYSE:LLY) is one of billionaire Stan Druckenmiller's top stock picks with huge upside potential. Bernstein SocGen Group reaffirmed its Outperform rating and $1,100 price target for Eli Lilly & Company (NYSE:LLY) on June 13 ahead of the 85th Annual Meeting of the American Diabetes Association. Pixabay/Public Domain The firm outlined a number of crucial data presentations that Eli Lilly & Company (NYSE:LLY) is expected to provide at the next meeting. One of these is the full description of the ACHIEVE-1 study, which is the first phase 3 trial from the late-stage clinical program of orforglipron. Bernstein is especially keen to acquire more information on the negative event profile and discontinuation rates, even if topline data is already available. Additionally, Eli Lilly & Company (NYSE:LLY) will provide information about its muscle-wasting medication, bimagrumab. When paired with tirzepatide, this will be the first clinical data reported for an anti-muscle wasting agent used in conjunction with a GLP-1 receptor agonist, possibly hinting at future use cases. Eli Lilly & Company (NYSE:LLY) is a major global pharmaceutical company that develops, manufactures, and distributes a wide range of drugs. Founded in 1876, it has grown to become one of the world's largest pharmaceutical companies. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
